News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
INTERVENT merges 25 years of health coaching with AI chatbots
INTERVENT Health AI combines clinical health coaching data with conversational AI. The startup aims to bring evidence-backed behavior change to enterprise wellness programs.
Pharma Giants Bet $50M on World Cup Ads as FDA Tightens Scrutiny
Sanofi and Amgen partner with US host cities for 2026 World Cup visibility. But drugmakers face heightened regulatory risk as FDA cracks down on misleading pharma commercials.
Roche's colon cancer combo hits FDA priority review with 50% death-risk cut
FDA grants priority review for Tecentriq plus chemotherapy in stage III colon cancer. Phase III data showed 86% disease-free survival at 36 months versus 76% with chemotherapy alone.
Akeso's gumokimab wins China approval for psoriasis with 94.6% clearance at week 12
Akeso's IL-17 inhibitor achieved near-complete skin clearance in Phase III trials and requires only 17 injections yearly. The drug is now approved in China for moderate-to-severe plaque psoriasis.
Indena and Chemi partner on peptide drug conjugates manufacturing
Two European CDMOs are positioning themselves to supply the infrastructure for peptide drug conjugates, a class of targeted cancer therapies gaining traction as alternatives to antibody drug conjugates. Learn what's driving adoption.
Novo's Wegovy pill wins UK approval as Eli Lilly fight intensifies
UK regulator approves oral semaglutide for obesity, but NHS coverage remains unclear. Meanwhile, 55,000 patients queue on private platforms and Novo reports 3M US prescriptions in five months.
Daiichi Sankyo targets top-five oncology by 2035 with $19.1B ADC pipeline
Japanese pharma Daiichi Sankyo plans to invest $18.5B in R&D over five years and expects DXd antibody-drug conjugates to generate $19.1B in peak sales. How it plans to compete beyond Enhertu.
Curia tackles steroid API supply with particle size control
Olivier Roux, Senior Director at Curia, explains how the CDMO simplifies manufacturing of corticosteroids and hormonal therapies—molecules used to treat asthma, autoimmune disease, and diabetes—and prepares for next-generation innovation.
Gorilla Adenovirus Skips Liver, Targets Tumors Naturally
ReiThera's gorilla adenovirus vector avoids pre-existing human immunity and liver sequestration while replicating selectively in cancer cells. The platform carries 36 kilobases of genetic cargo, 8x larger than AAV alternatives.
Three biotech labs bypass antibiotic resistance without creating new resistance
Researchers at three institutions developed three separate approaches to kill antibiotic-resistant bacteria using gold nanoparticles, modified bacteria, and phage therapy. None triggered resistance in sustained treatment—a major departure from conventional antibiotics.
Full-Length DMD Gene Delivered via Engineered Vesicles, Restores Muscle Function in Mice
Researchers engineered extracellular vesicles to deliver complete dystrophin mRNA to skeletal muscle without viral vectors. The approach restored muscle strength in DMD models and showed safety in primates.
Rat genetic study pins cocaine addiction to liver enzyme, not just brain
UC San Diego researchers used nearly 900 genetically diverse rats to map six genetic regions tied to compulsive cocaine use. A liver enzyme (Ces1) emerged as a potential drug target—shifting focus from brain-only addiction models.